Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22031656 | 0.84 | MAPT (0.56) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL459968 | 0.81 | MAPT (0.76) | MAPTRECQLALDH1A1MEN1KMT2A | |
| SCHEMBL8069112 | 0.81 | MAPT (0.71) | MAPTRECQLALDH1A1MEN1KMT2A | |
| SCHEMBL3656638 | 0.78 | ALDH1A1 (0.76) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL470231 | 0.77 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL459207 | 0.77 | ALDH1A1 (0.57) | MAPTALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL19606264 | 0.76 | MAPT (0.50) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL456801 | 0.75 | MAPT (0.55) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL30164114 | 0.74 | ALDH1A1 (0.47) | MAPTRECQLALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1114152 | 0.74 | MAPT (0.60) | MAPTRECQLALDH1A1HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614052-B1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2614052-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | Bristol-Myers Squibb Company (US) | 2013-07-17 | — | — | EP | disclosed |
| CN-103201268-A | Novel piperazine analogs as broad-spectrum influenza antivirals | BRISTOL MYERS SQUIBB CO | 2013-07-10 | — | — | CN | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| WO-2012033736-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | ZC3HAV1, ZC3HAV1L, HCRTR1 | MAPT 4757/4885RECQL 1356/4885ALDH1A1 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.